Related Experiment Video
Updated: May 4, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.7K
How many people inject insulin? UK estimates from 1991 to 2010
S E Holden1, E A M Gale, S Jenkins-Jones
1Cochrane Institute of Primary Care and Public Health, School of Medicine, Cardiff University, The Pharma Research Centre, Cardiff Medicentre, Cardiff, UK.
Diabetes, Obesity & Metabolism
|January 14, 2014
Summary
The number of people using insulin in the UK tripled between 1991 and 2010. This increase was primarily driven by a significant rise in insulin use among individuals with type 2 diabetes.
Area of Science:
- Endocrinology
- Public Health
- Epidemiology
Background:
- Insulin therapy is crucial for managing diabetes.
- Understanding insulin use trends is vital for healthcare planning.
Purpose of the Study:
- To estimate the prevalence of insulin use in the UK population.
- To determine the total number of insulin users and their diabetes type (Type 1 vs. Type 2).
- To analyze changes in insulin use patterns between 1991 and 2010.
Main Methods:
- Utilized the Clinical Practice Research Datalink (CPRD) to identify insulin prescriptions.
- Attributed diabetes diagnoses (Type 1 or Type 2) to identified patients.
- Calculated annual prevalence rates and applied them to UK population data.
Main Results:
- Crude prevalence of insulin use rose from 2.43 to 6.71 per 1000 population (1991-2010).
- Insulin use in Type 2 diabetes increased substantially, from 0.67 to 4.34 per 1000 population.
- Total insulin users grew from 137,000 to 421,000; use of insulin alone decreased significantly.
Conclusions:
- The number of individuals using insulin in the UK trebled between 1991 and 2010.
- This significant increase is largely attributed to a rise in insulin prescriptions for Type 2 diabetes management.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
01:27Insulin Formulations: Types and Delivery
1.2K
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
1.2K
01:30Production of Pharmaceuticals
94
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...
94
01:25Insulin: Biosynthesis, Chemistry, and Preparation
2.1K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
2.1K
01:22Diabetes Mellitus: Overview and Type I Subtype
5.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.5K
01:05Insulin Secretory Vesicles
6.3K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
6.3K